HIV-1 INFECTION

This early-stage study tested a new HIV vaccine called INO-6160 in 20 healthy adults without HIV. The vaccine uses synthetic DNA to teach the body to recognize HIV and includes an immune booster (IL-12). Some participants also received a booster shot with a different HIV protein.…

This study tested a mix of six plant extracts and vitamin C in 60 people with HIV/AIDS. The goal was to see if the natural formula could protect and increase CD4+ T cells and B cells, which are key immune cells damaged by HIV. Participants took the plant-based medication alongsid…

This study followed 27 people with HIV who had end-stage kidney disease and received a kidney transplant. Researchers wanted to see how many patients would have graft rejection within 6 months while taking a three-drug HIV regimen that included raltegravir. The goal was to better…

This study tested a smartphone app called START to help men who have HIV and use stimulants like methamphetamine stick to their HIV medication. The goal was to see if the app could lower the amount of virus in their blood. The study included 286 men and focused on improving treat…

This study tested if Trogarzo, an HIV medicine, can be given as a quick 30-second injection instead of a slow 15-minute IV drip. Researchers also tried giving it as a muscle shot. 43 people with stable HIV who already used Trogarzo took part. The goal was to see if these faster m…

This study tested whether taking fecal transplants (FMT) in capsules could reduce gut inflammation in people with HIV who are on antiretroviral therapy (ART) but have a low CD4/CD8 ratio. Twenty participants were split into two groups: one received FMT capsules and the other rece…

This study tested an experimental drug called PRO 140 in 6 adults with HIV whose current medications were no longer controlling the virus. The goal was to see if adding PRO 140 could lower the amount of HIV in their blood. The trial lasted 25 weeks and combined PRO 140 with other…

This study tested whether adults with HIV-1 whose virus is already under control could safely switch from a daily pill to a once-weekly combination of two experimental drugs (islatravir and MK-8507). 161 participants took part. The main goal was to check for side effects and see …

This early-stage study tested a new gene therapy in 2 HIV patients who also had a high-risk lymphoma. The goal was to see if it's safe to add a special anti-HIV gene to their blood stem cells and immune cells before a stem cell transplant. The approach aims to help control HIV wh…

This study tested a two-drug combination (raltegravir and etravirine) in 170 people with HIV who were 45 or older and already had the virus under control. After switching from a standard three-drug regimen, 99% maintained viral suppression at 48 weeks and 98.7% at 96 weeks. The a…

This study tested a new once-daily combination pill (doravirine/islatravir) in 599 adults newly diagnosed with HIV who had never taken HIV medication. The goal was to see if the new pill could control the virus as well as or better than a standard three-drug regimen. Results show…

This study tested an experimental drug, STP0404, in 25 adults with HIV-1 who had never taken HIV medicines before. The goal was to see how well the drug lowers the amount of virus in the blood and if it is safe. Participants took the drug or a placebo for 10 days, and researchers…

This study looked at how well a new HIV drug (dolutegravir) works with standard anti-rejection medicines in 19 people who had an organ transplant and also have HIV. The goal was to make sure the drugs don't interfere with each other and are safe. Results help doctors choose bette…

This study tested two different once-daily HIV drug combinations in 101 people recently infected with HIV. The goal was to see which combo better reduces the amount of HIV DNA hiding in immune cells after 48 weeks. While both treatments control the virus, the study focuses on shr…

This study tested whether a stronger tuberculosis (TB) treatment could reduce deaths in people with HIV who have very low CD4 counts (≤100). Over 1,300 hospitalized adults and teens received either an intensified regimen (higher doses of some TB drugs plus steroids) or the standa…

This study tested whether a combination of two lab-made HIV antibodies (VRC07-523LS and CAP256V2LS) followed by an immune-boosting drug (vesatolimod) is safe for women with HIV who are already on standard antiretroviral therapy (ART). The 20 participants were all women from a spe…

This study looked at 33 adults with well-controlled HIV who switched from a monthly injectable treatment (CAB+RPV) to a daily oral pill (B/F/TAF). The main goal was to check safety over 12 weeks. Results showed the oral pill was safe and well-tolerated, offering a convenient alte…

This study tested a combination of two lab-made antibodies (TMB-365 and TMB-380) in 51 adults with HIV whose virus was already well-controlled by daily oral medication. The goal was to see if these antibodies, given as intravenous infusions every 8 weeks, could safely keep the vi…

This study looked back at medical records of 800 people with HIV to compare two different drug combinations: a two-drug regimen (DTG/3TC) and a three-drug regimen (BIC/F/TAF). The goal was to see how well each kept the virus under control over 48 weeks. The study focused on real-…

This study tested a program to help people over 50 living with HIV build resilience and better cope with daily stress. 106 participants from an HIV clinic used daily text messaging to track their stress and coping skills. The goal was to see if the program improved their resilien…

This study looked at how much HIV medication passes from mother to baby through breastmilk. Sixteen mothers living with HIV who chose to breastfeed provided blood and milk samples at 1, 3, and 6 months after giving birth. Researchers measured drug levels to calculate how much med…

This study looked at 80 HIV patients on long-term antiretroviral therapy to understand why their gut immune barrier remains damaged. The leaky gut allows bacteria to enter the blood, causing harmful inflammation. Researchers measured immune cells in blood and gut tissue to find o…

This study looked at how a single dose of methamphetamine affects HIV activity in 14 people with HIV who were on effective treatment and had no history of meth use. Researchers measured changes in HIV production and inflammation over 4 hours. The goal was to understand how meth m…

This study tested whether the BCG vaccine, normally used for tuberculosis, could reduce the amount of hidden HIV in the body. 60 people with HIV on stable antiretroviral therapy received either the BCG vaccine or a placebo. The main goal was to measure changes in the HIV reservoi…

This study looked at how moderate drinking impacts inflammation and brain health in people with HIV. Researchers gave alcohol to 76 healthy volunteers and people with HIV, then used blood tests and brain scans to measure changes. The goal was to better understand the risks of alc…

This study looked at how well HIV medications reach different parts of the body where the virus can hide. Twenty men with HIV who were on stable treatment provided samples of lymph nodes, fat, rectal tissue, and sperm. The goal was to measure drug levels in these areas to better …